Skip to content

About Amber Implants

We are an innovative and ambitious med-tech company that is working tirelessly to improve the quality of life for patients suffering from a variety of vertebral fractures.

Our Story​

The story of Amber Implants began at Delft University of Technology, where founders Dr. Banafsheh Sajadi and Dr. Mohammad Ahmadi completed their Ph.D. studies and began translating advanced engineering concepts into innovative orthopaedic implant designs.

What started as a shared vision for better implant solutions has grown into a medical technology company focused on advancing spine care through minimally invasive reconstruction and stabilization technologies. Today, Amber Implants is supported by a rapidly growing team of engineers, clinicians, regulatory specialists, and commercialization leaders working together to bring meaningful innovation to vertebral fracture treatment.

As the company moves toward broader commercialization, Amber Implants continues to build on its scientific foundation, entrepreneurial spirit, and commitment to quality. The company operates in accordance with ISO 13485 and FDA guidelines for medical device development and manufacturing.

Our Mission

Quality

To relentlessly advance the treatment of vertebral fractures by delivering innovative, high-quality medical technologies that improve patient outcomes, restore function, and elevate quality of life.

Commitment

Amber Implants is committed to and accountable for advancing diversity, equity, and inclusion in all its forms.

Team

At Amber Implants, we strive for a healthy, inclusive, and high-performing organization where talented people are empowered to contribute to meaningful innovation in spine care.

Our team

Banafsheh
Sajadi, PhD

CO-FOUNDER, COO

Mohammad
Ahmadi, PhD

CO-FOUNDER, CTO

Vincent
Gardès

CEO

Looking for all the employees of Amber Implants? Check out our LinkedIn page.

Interested in joining our team? Check our available positions or submit your application by clicking the button below.

Company Timeline

2018
Company Launch

Company launches and receives seed funding.

2019
Collaborations

Company expands its research footprint by participating in multiple European and national research initiatives and collaborating with 20 partners in support of orthopaedic implant development.

2020
VCFix® Spinal System

VCFix® advanced through early feasibility work and project planning, establishing the foundation for subsequent product development and regulatory engagement.

2021
Breakthrough Device Designation, Series A Fundraising

VCFix® Spinal System receives Breakthrough Device Designation from the U.S. FDA, supporting priority review during development.
Company receives Series A funds.

2022
Finishing Pre-clinical Activities

Company finishes pre-clinical activities and regulatory phase.

2023
First-in-Human Trials

Company successfully completes the First-in-Human clinical trials, including follow-up. For more information, see news item.

2025
Pivotal EXPAND Study

Company receives approval from both the Ethics Committee (EC) and BfArM in Germany for pivotal EXPAND study of the VCFix® Spinal System.

2026
VCFix® Spinal System Launch in US

Introduction of VCFix® Spinal System with cement in the US market.